MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--Rainbow Coral Corp.’s (OTCBB: RBCC) joint venture partner, Nano3D Biosciences (n3D), has developed the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening, and the global market potential for the device points to very bright future for the company.
Help employers find you! Check out all the jobs and post your resume.
